How are you taking part in this consultation?

You will not be able to change how you comment later.

You must be signed in to answer questions

  • Question on Consultation

    • Has all of the relevant evidence been taken into account?

  • Question on Consultation

    • Are the summaries of clinical and and cost effectiveness reasonable interpretations of the evidence?

  • Question on Consultation

    • Are the recommendations sound and a suitable basis for guidance to the NHS?

  • Question on Consultation

    • Are there any aspects of the recommendations that need particular consideration to ensure we avoid unlawful discrimination against any group of people on the grounds of race, gender, disability, religion or belief, sexual orientation, age, gender reassignment, pregnancy and maternity?
The content on this page is not current guidance and is only for the purposes of the consultation process.

Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis

Closed for comments This consultation ended on at   Request commenting lead permission

2 Information about avacopan

Marketing authorisation indication

2.1 Avacopan (Tavneos, Vifor Pharma), 'in combination with a rituximab or cyclophosphamide regimen, is indicated for the treatment of adult patients with severe, active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA)'.

Dosage in the marketing authorisation

2.2 The dosage schedule will be available in the summary of product characteristics for avacopan.

Price

2.3 The company considers the list price of avacopan to be confidential. The company has a commercial arrangement, which would have applied if the technology had been recommended.